Estrogen/progesterone receptor and HER2 discordance between primary tumor and brain metastases in breast cancer and its effect on treatment and survival.

ABSTRACT:

Background

Breast cancer treatment is based on estrogen receptors (ERs), progesterone receptors (PRs), and human epidermal growth factor receptor 2 (HER2). At the time of metastasis, receptor status can be discordant from that at initial diagnosis. The purpose of this study was to determine the incidence of discordance and its effect on survival and subsequent treatment in patients with breast cancer brain metastases (BCBM).

Methods

A retrospective database of 316 patients who underwent craniotomy for BCBM between 2006 and 2017 was created. Discordance was considered present if the ER, PR, or HER2 status differed between the primary tumor and the BCBM.

Results

The overall receptor discordance rate was 132/316 (42%), and the subtype discordance rate was 100/316 (32%).

SUBMITTER: Sperduto PW 

PROVIDER: S-EPMC7523450 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature